Paradigm Biopharmaceuticals Limited announced three recent senior executive appointments. Beverley Huttmann, Justin Cahill and Catherine Stapledon have all joined the Paradigm team, bringing with them skills and experience that further strengthen the capabilities of Paradigm's management, as the company continues to move toward commercialization. Beverley will be responsible for developing and implementing commercial strategy including partnerships, licensing, pricing and reimbursement, product differentiation, patient and physician acceptance and life cycle management. Chief Financial Officer, Justin Cahill, has over 20 years' experience in strategic finance roles across a broad spectrum of industries and global organizations. As Paradigm's operations expand and become more global, Justin will oversee the financial management of and control over Paradigm's increasingly complex activities. R&D Translational Scientist, Catherine Stapledon, will be working alongside Chief Science Officer, Ravi Krishnan.